Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant 500 mg vs 250 mg in postmenopausal ER+ advanced breast cancer
CTR20132392Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fulvestrant in breast cancer, sponsored by AstraZeneca. Started May 2014; status: completed.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20132392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132392.